Study Title: A Phase II, Single Arm, Non-randomized Study of Alpelisib (BYL719) in Combination with Continued Endocrine Therapy Following Progression on Endocrine Therapy in Hormone Receptor Positive, HER2 Negative, PIK3CA Mutant Metastatic Breast Cancer: Big Ten Cancer Research Consortium BTCRC-BRE19-409
- Closed to Accrual at:
- Learn more:
- Publications and Presentations
- Trials in Progress: 2022 ASCO Annual Meeting
Study Contact: studies@hoosiercancer.org; (317) 921-2050.
Subscribe to the Big Ten CRC NewsletterXFacebookYouTube